A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerChanghoon Yoo, Jenn-Jiang Hwang, Je Hyeong Kim et al.|British Journal of Cancer|2009Cited by 170